Ekaterina Manuilova, Isabelle Schrurs, Sandra Rutz, Silja McIlwrick, Oliver Goldhardt, Patrick Sommer, Timo Grimmer
{"title":"Elecsys CSF AD immunoassays: Sample stability for a new pre-analytical protocol for fresh CSF","authors":"Ekaterina Manuilova, Isabelle Schrurs, Sandra Rutz, Silja McIlwrick, Oliver Goldhardt, Patrick Sommer, Timo Grimmer","doi":"10.1002/alz.70797","DOIUrl":null,"url":null,"abstract":"<div>\n \n <section>\n \n <h3> INTRODUCTION</h3>\n \n <p>Amyloid beta 1–42 (Aβ42), tau phosphorylated at threonine-181 (p-tau181), and total tau (t-tau) are cerebrospinal fluid (CSF) biomarkers for Alzheimer's disease diagnosis.</p>\n </section>\n \n <section>\n \n <h3> METHODS</h3>\n \n <p>We prospectively examined storage time, temperature, and freeze/thaw effects on Aβ42, p-tau181, and t-tau stability in fresh CSF samples using Elecsys<sup>®</sup> CSF immunoassays.</p>\n </section>\n \n <section>\n \n <h3> RESULTS</h3>\n \n <p>All three biomarkers were stable at 2–8°C for ≤15 days, and −25°C to −15°C for ≤8 weeks, and after one freeze/thaw cycle. p-Tau181 and t-tau were also stable at 15–25°C for ≤8 days and at −25°C to −15°C for 12–15 weeks. Aβ42 recovery declined slightly after storage at 15–25°C for ≤8 days and −25°C to −15°C for 12–15 weeks, and one freeze/thaw cycle.</p>\n </section>\n \n <section>\n \n <h3> DISCUSSION</h3>\n \n <p>For optimal immunoassay performance, it is recommended to store CSF samples at 15–25°C for ≤5 days, 2–8°C for ≤15 days, and −25°C to −15°C for ≤8 weeks.</p>\n </section>\n \n <section>\n \n <h3> Highlights</h3>\n \n <div>\n <ul>\n \n <li>Cerebrospinal fluid (CSF) biomarkers aid in Alzheimer's disease diagnosis.</li>\n \n <li>Fresh CSF stored at 15–25°C for ≤5 days is optimal for Elecsys CSF immunoassays.</li>\n \n <li>Fresh CSF stored at 2–8°C for ≤15 days is optimal for Elecsys CSF immunoassays.</li>\n \n <li>Fresh CSF stored at −25°C to −15°C for ≤8 weeks is optimal for Elecsys CSF immunoassays.</li>\n </ul>\n </div>\n </section>\n </div>","PeriodicalId":7471,"journal":{"name":"Alzheimer's & Dementia","volume":"21 10","pages":""},"PeriodicalIF":11.1000,"publicationDate":"2025-10-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://alz-journals.onlinelibrary.wiley.com/doi/epdf/10.1002/alz.70797","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer's & Dementia","FirstCategoryId":"3","ListUrlMain":"https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/alz.70797","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
INTRODUCTION
Amyloid beta 1–42 (Aβ42), tau phosphorylated at threonine-181 (p-tau181), and total tau (t-tau) are cerebrospinal fluid (CSF) biomarkers for Alzheimer's disease diagnosis.
METHODS
We prospectively examined storage time, temperature, and freeze/thaw effects on Aβ42, p-tau181, and t-tau stability in fresh CSF samples using Elecsys® CSF immunoassays.
RESULTS
All three biomarkers were stable at 2–8°C for ≤15 days, and −25°C to −15°C for ≤8 weeks, and after one freeze/thaw cycle. p-Tau181 and t-tau were also stable at 15–25°C for ≤8 days and at −25°C to −15°C for 12–15 weeks. Aβ42 recovery declined slightly after storage at 15–25°C for ≤8 days and −25°C to −15°C for 12–15 weeks, and one freeze/thaw cycle.
DISCUSSION
For optimal immunoassay performance, it is recommended to store CSF samples at 15–25°C for ≤5 days, 2–8°C for ≤15 days, and −25°C to −15°C for ≤8 weeks.
Highlights
Cerebrospinal fluid (CSF) biomarkers aid in Alzheimer's disease diagnosis.
Fresh CSF stored at 15–25°C for ≤5 days is optimal for Elecsys CSF immunoassays.
Fresh CSF stored at 2–8°C for ≤15 days is optimal for Elecsys CSF immunoassays.
Fresh CSF stored at −25°C to −15°C for ≤8 weeks is optimal for Elecsys CSF immunoassays.
期刊介绍:
Alzheimer's & Dementia is a peer-reviewed journal that aims to bridge knowledge gaps in dementia research by covering the entire spectrum, from basic science to clinical trials to social and behavioral investigations. It provides a platform for rapid communication of new findings and ideas, optimal translation of research into practical applications, increasing knowledge across diverse disciplines for early detection, diagnosis, and intervention, and identifying promising new research directions. In July 2008, Alzheimer's & Dementia was accepted for indexing by MEDLINE, recognizing its scientific merit and contribution to Alzheimer's research.